|Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension|
|Ge Jian1; Sun Xing-huai2; Wang Ning-li3; Zhao Jia-liang4; Wu Ling-ling5; Chen Xiao-ming6; Wang Zhi-xin7; Li, Benny7|
|关键词||travoprost prostaglandin analogue intraocular pressure glaucoma|
|刊名||CHINESE MEDICAL JOURNAL|
|WOS标题词||Science & Technology|
|类目[WOS]||Medicine, General & Internal|
|研究领域[WOS]||General & Internal Medicine|
|关键词[WOS]||FP PROSTAGLANDIN RECEPTOR ; CALCIUM MOBILIZATION ; TIMOLOL 0.5-PERCENT ; MULTICENTER TRIAL ; CLINICAL-TRIAL ; LATANOPROST ; BIMATOPROST ; 6-MONTH ; MEDICATION|
Background Travoprost has been widely used for the treatment of patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The aim of this study was to evaluate the intraocular pressure (IOP) lowering efficacy of travoprost 0.004% monotherapy in patients previously treated with other topical hypotensive medications, and in previously untreated patients.
Methods This open-label, 12-week study in 1651 adult patients with ocular hypertension or open-angle glaucoma who were untreated or required a change in therapy (due to either inadequate efficacy or safety issues) as judged by the investigator was conducted at 6 sites in China. Previously treated patients were instructed to discontinue their prior medications at the first visit. All the patients were dosed with travoprost 0.004% once-daily at 8 p.m. in both eyes for 12 weeks. Efficacy and safety evaluations were conducted at week 4 and 12. IOP measurements were performed at the same time of day at the follow-up visits.
Results For patients transitioned to travoprost, mean IOP reductions from baseline in untreated and treated patients with different prior medications at week 12 were: latanoprost, (4.3+/-4.6) mmHg; beta-blocker, (6.3+/-4.0) mmHg; a-agonist, (7.5+/-4.3) mmHg; topical carbonic anhydrase inhibitors, (8.0+/-4.9) mmHg. All mean IOP changes from baseline were statistically significant (P <0.001). No treatment-related serious adverse events were reported in this study.
Conclusions In patients treated with other hypotensive medications or untreated, the IOP reduction with travoprost was significant. The results of this study demonstrated the potential benefit of using travoprost as a replacement therapy in order to ensure adequate IOP control. Travoprost administered once daily was safe and well tolerated in patients with glaucoma or ocular hypertension. Chin Med J 2010;123(11):1417-1421
|资助机构||Alcon Research Ltd., Fort Worth, TX|
|作者单位||1.Peking Univ, Hosp 3, Ctr Eye, Beijing 100191, Peoples R China|
2.Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China
3.Fudan Univ, Sch Med, Dept Ophthalmol, Eye Ear Nose & Throat Hosp, Shanghai 200031, Peoples R China
4.Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing Ophthalmol & Visual Sci Key Lab, Beijing 100730, Peoples R China
5.Alcon Res Ltd, Ft Worth, TX 76134 USA
6.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China
7.Sichuan Univ, W China Hosp, Dept Ophthalmol, Chengdu 610041, Sichuan, Peoples R China
|Ge Jian,Sun Xing-huai,Wang Ning-li,et al. Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension[J]. CHINESE MEDICAL JOURNAL,2010,123(11):1417-1421.|
|APA||Ge Jian.,Sun Xing-huai.,Wang Ning-li.,Zhao Jia-liang.,Wu Ling-ling.,...&Li, Benny.(2010).Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension.CHINESE MEDICAL JOURNAL,123(11),1417-1421.|
|MLA||Ge Jian,et al."Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension".CHINESE MEDICAL JOURNAL 123.11(2010):1417-1421.|